Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

696.03 +1.04 (+0.15%)
Streaming Delayed Price Updated: 2:56 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
57 58 Next >
News headline image
MAIA Secures FDA Clearance Of IND Application For THIO For Non-Small Cell Lung Cancer ↗
MAIA Biotechnology, Inc. (AMEX: MAIA) announced that the U.S. 
Via Benzinga
News headline image
Regeneron Pharmaceuticals Unusual Options Activity ↗
 
Via Benzinga
News headline image
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Stock Split Watch: Is Regeneron Pharmaceuticals Next? ↗
If the biotech does split its stock, it will be a first for the company. 
Via The Motley Fool
News headline image
Examining the Quality Attributes of NASDAQ:REGN. ↗
Why the quality investor may take a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN). 
Via Chartmill
News headline image
Analyst Expectations for Regeneron Pharmaceuticals's Future ↗
 
Via Benzinga
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 9/19 Morning Trading
Via Investor Brand Network
News headline image
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Three Of Our Top Picks For Your Healthcare Portfolio ↗
Amidst macro uncertainty, healthcare stocks should outperform. 
Via Talk Markets
News headline image
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today ↗
 
Via Benzinga
News headline image
Peering Into Regeneron Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
Check Out What Whales Are Doing With REGN ↗
 
Via Benzinga
News headline image
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 9/8 Morning Trading
Via Investor Brand Network
News headline image
If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,000 Today ↗
 
Via Benzinga
News headline image
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
News headline image
This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost ↗
A higher-dose version of Eylea will help the company fight off competition and increase revenue. 
Via The Motley Fool
News headline image
3 Stocks to Buy to Ride Europe’s Coming Market Surge ↗
With Europe’s markets looking to perform better in the second half of 2023, here are three European stocks to buy to ride the wave. 
Via InvestorPlace
News headline image
AI Integration In Biotech & Pharma: Companies Positioned To Benefit ↗
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care.... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2023 ↗
 
Via Benzinga
News headline image
New to Investing? Here's How You Can Get Started With $500. ↗
You don't have to invest a lot to start building a winning portfolio. 
Via The Motley Fool
News headline image
3 Unstoppable Growth Stocks to Buy Right Now ↗
These healthcare stocks show no signs of slowing down. 
Via The Motley Fool
News headline image
Regeneron Provides Update on Planned Chief Financial Officer Transition
Robert E. Landry to retire effective February 2024; Christopher Fenimore, long-standing Senior Vice President, Head of Accounting and Controller, to assume CFO role 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Announces Updates to Board of Directors
Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., join Regeneron’s Board of Directors 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Top Biotech Stocks to Buy in September ↗
There is rarely a bad time to buy stocks with massive upside potential. 
Via The Motley Fool
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.